menu
    • menu
    [{"orgOrder":0,"company":"AVAS Pharmaceuticals","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mexiletine","moa":"||Na channel-alpha-subunit","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AVAS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AVAS Pharmaceuticals \/ AVAS Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AVAS Pharmaceuticals \/ AVAS Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by AVAS Pharmaceuticals

    Menu

    AVAS Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AVAS Pharmaceuticals

                            Italy arrow
                            EPSC
                            Not Confirmed

                            AVAS Pharmaceuticals

                            Italy arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mexiletine,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : Lupin Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lupin and Avas Launch NaMuscla in Italy

                            Details : NaMuscla (mexiletine hydrochloride) is a Sodium channel alpha subunit blocker, being evaluated for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders.

                            Product Name : Namuscla

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 28, 2025

                            Lead Product(s) : Mexiletine,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : Lupin Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth